Sponsor
Novartis Pharmaceuticals
156 PBAC submissions on file, active 2005–2025. 71% have been recommended.
Submissions
156
2005 → 2025
Win rate
71 %
110 recommended of 156 bucketable
Drugs
60 · 52 listed
unique molecules submitted
PBS spend captured
$371M
FY-latest govt benefit on owned drugs
Drug portfolio
Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.
Therapy area mix Oncology 30 Haematology 22 Ophthalmology 17 Neurology 17 Respiratory 14 Cardiovascular 11 Endocrinology 10 Rheumatology 8 Dermatology 8 Rare disease 7
Activity by year 2005 (3) · 2006 (4) · 2007 (6) · 2008 (7) · 2010 (8) · 2011 (7) · 2012 (7) · 2013 (13) · 2014 (11) · 2015 (11) · 2016 (11) · 2017 (7) · 2018 (8) · 2019 (8) · 2020 (11) · 2021 (5) · 2022 (6) · 2023 (5) · 2024 (10) · 2025 (8)
Rejection patterns
Across 38 Not recommended decisions on file.
2× teratogenicity2× unacceptably high cost-effectiveness ratio1× Uncertain claim of non-inferior safety compared to aflibercept1× emergent post-market safety signal for retinal vasculitis and/or retinal vascular occlusion with or without intraocular inflammation1× higher ocular serious adverse event rate (3.4% vs 1.5%)Open on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.